Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector




















Sort by: Date|Relevance

CureVac, BioNTech, Valeo Pharma: Where is there still potential?

The race for vaccines against Covid-19 is fierce. Every day there are new water level reports - from setbacks to breakthroughs, everything is there. The Tübingen-based Company CureVac ( NASDAQ: CVAC ) recently started its phase study IIa in Peru and Panama. Around 700 people...

Better & Cheaper than the Competition: A Deeper Look at a Revolutionary EV Charging Platform

(Image courtesy of IONiX Pro Battery Technologies Inc.) From new tech, apps, and delivering its products to customers, 2021 has been a busy year for Extreme Vehicle Battery Technologies Corp. ( CSE: ACDC , Forum ) and its new, cutting-edge battery storag...

This is Why the Secular Bull is Going to Last

To me the most important engineering puzzle policy makers around the world have to solve for the years ahead is how to get the economic machine to produce economic well-being for most people when monetary policy does not work …. Ray Dalio Economies are human constructs, n...

FOMC Minutes Reveal an Important Shift That’s Key for Gold, Too

Yesterday, the Fed released minutes from its last meeting . They show an important shift among the meeting participants. In September, the FOMC turned more worried about the state of the U.S. economy, while just six weeks later in October, the Committee felt more optimist...

Consumer Discretionary Sector and Corporate Bonds On Verge of Sell-off

I have been warning of a peak in the markets and a continued capital shift in the global economy that continued to push the NASDAQ and DOW towards new all-time highs while the foundations of the global markets continued to weaken. I authored dozens of research posts regar...

Axsome Therapeutics Investors Awaken to Positive Outcome in Phase 2 Narcolepsy Trial

Axsome Therapeutics shares traded 14% higher today after the company reported that its narcolepsy drug candidate AXS-12 achieved its primary endpoint in the Phase 2 CONCERT Study. This morning before U.S. markets opened, clinical-stage biopharmaceutical company Axsom...

Axsome Therapeutics Shares Open 82% Higher on Phase 3 MDD Trial Outcome

Axsome Therapeutics shares reached a new 52-week high price today after the company reported that its AXS-05 drug achieved primary endpoint in the GEMINI Phase 3 trial in Major Depressive Disorder. The firm indicated that the positive results support a New Drug Application fil...

Shipping Rates Plunge, Commodities and Stocks May Follow

An almost immediate reaction to the Coronavirus outbreak in China and throughout most of the world has sent shock-wave through the global markets – particularly seen in Shipping and Oil. The actions within China to attempt to contain the virus spread include shutting down en...

Adaptive Fibonacci Suggests Much Lower Prices Yet To Come – Part I

Our Adaptive Fibonacci Price Modeling system suggests a much deeper price move is in the works and the current price rally will likely end near resistance levels identified by the Adaptive Fibonacci Price Modeling system. We are posting this research post for friends and fol...

Avadel Shares Rise and Shine on Positive Phase 3 Narcolepsy Study Findings

Avadel Pharmaceuticals' shares traded 25% higher reaching a new 52-week high price after the company reported positive topline results from its Pivotal Phase 3 REST-ON trial of FT218 for the treatment of excessive daytime sleepiness and cataplexy in narcolepsy patients. ...
1 2 3 4